Literature DB >> 23800891

HER2 in gastric cancer: an immunohistochemical study on tissue microarrays and the corresponding whole-tissue sections with a supplemental fish study.

Gorana Gasljevic1, Janez Lamovec, Juan Antonio Contreras, Vesna Zadnik, Mateja Blas, Slavko Gasparov.   

Abstract

Since focal HER2 expression is an issue in GC, TMA construction from the paraffin-embedded surgically-obtained tissue may not reflect its real status. The aim of this study was to assess the HER2 status in tissue microarrays (TMAs) and the corresponding whole sections using HercepTest immunohistochemistry (IHC), and to correlate it and to assess the concordance of HER2 IHC and fluorescence in situ hybridization (FISH) in TMAs. Concordance of the HER2 expression status for 302 cases of gastric cancer using 9 paired TMAs was evaluated using a 2-mm core size and 305 corresponding whole sections. Concordance of the IHC and FISH HER2 status was compared. In addition,, the HER2 status was compared to clinicopathological characteristics and patients' survival. Using the whole-section approach, HER2 over-expression was found in 25.2 % (HER2 3+ 6.6 %, HER2 2+ 18.7 %) of tumours. The overall concordance of IHC between the cores and the whole section was 84.9 %; 15.1 % of the tumours showed HER2 amplification. The overall concordance of IHC and FISH on cores was 75.7 %. The level of amplification correlated with the IHC score. Relationship between the intestinal and papillary types and tumour grade was observed for tumours with over-expression and amplification, whereas tumour location was related only to over-expression. There was a statistically significant difference in the overall survival of the patients, which was related to HER2 amplification. In conclusion, good concordance of the IHC HER2 results between tissue cores in TMA and whole sections, and excellent concordance of the IHC and FISH results on tissue cores was found. At least a part of the observed IHC HER2 heterogeneity could very likely be explained by fixation artifacts. With adequate fixation, a higher concordance of IHC HER2 between the cores and the whole sections can be expected. The TMA approach could enable an easier analysis of more than one representative tumour block.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23800891     DOI: 10.1007/s12253-013-9654-9

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  29 in total

1.  c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems.

Authors:  H Allgayer; R Babic; K U Gruetzner; A Tarabichi; F W Schildberg; M M Heiss
Journal:  J Clin Oncol       Date:  2000-06       Impact factor: 44.544

2.  HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment.

Authors:  Pamela L Kunz; Amirkaveh Mojtahed; George A Fisher; James M Ford; Daniel T Chang; Raymond R Balise; Charles D Bangs; Athena M Cherry; Reetesh K Pai
Journal:  Appl Immunohistochem Mol Morphol       Date:  2012-01

3.  Survival after gastric adenocarcinoma resection: eighteen-year experience at a single institution.

Authors:  Steven C Cunningham; Farin Kamangar; Min P Kim; Sommer Hammoud; Raqeeb Haque; Anirban Maitra; Elizabeth Montgomery; Richard E Heitmiller; Michael A Choti; Keith D Lillemoe; John L Cameron; Charles J Yeo; Richard D Schulick
Journal:  J Gastrointest Surg       Date:  2005 May-Jun       Impact factor: 3.452

4.  Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab.

Authors:  M Tanner; M Hollmén; T T Junttila; A I Kapanen; S Tommola; Y Soini; H Helin; J Salo; H Joensuu; E Sihvo; K Elenius; J Isola
Journal:  Ann Oncol       Date:  2005-02       Impact factor: 32.976

Review 5.  Targeting HER2 in other tumor types.

Authors:  S Scholl; P Beuzeboc; P Pouillart
Journal:  Ann Oncol       Date:  2001       Impact factor: 32.976

Review 6.  HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target.

Authors:  C Gravalos; A Jimeno
Journal:  Ann Oncol       Date:  2008-04-25       Impact factor: 32.976

7.  Low frequency of HER2 amplification and overexpression in early onset gastric cancer.

Authors:  Cathy B Moelans; Anya N Milne; Folkert H Morsink; G Johan A Offerhaus; Paul J van Diest
Journal:  Cell Oncol (Dordr)       Date:  2011-03-11       Impact factor: 6.730

8.  HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series.

Authors:  Heike Grabsch; Shivan Sivakumar; Sally Gray; Helmut E Gabbert; Wolfram Müller
Journal:  Cell Oncol       Date:  2010       Impact factor: 6.730

Review 9.  Emerging technologies for assessing HER2 amplification.

Authors:  Frédérique Penault-Llorca; Michael Bilous; Mitch Dowsett; Wedad Hanna; Robert Yoshiyuki Osamura; Josef Rüschoff; Marc van de Vijver
Journal:  Am J Clin Pathol       Date:  2009-10       Impact factor: 2.493

10.  Mixed-type gastric carcinomas exhibit more aggressive features and indicate the histogenesis of carcinomas.

Authors:  Hua-chuan Zheng; Xiao-han Li; Takuo Hara; Shinji Masuda; Xiang-hong Yang; Yi-fu Guan; Yasuo Takano
Journal:  Virchows Arch       Date:  2008-05       Impact factor: 4.064

View more
  4 in total

Review 1.  HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology.

Authors:  Angela N Bartley; Mary Kay Washington; Christina B Ventura; Nofisat Ismaila; Carol Colasacco; Al B Benson; Alfredo Carrato; Margaret L Gulley; Dhanpat Jain; Sanjay Kakar; Helen J Mackay; Catherine Streutker; Laura Tang; Megan Troxell; Jaffer A Ajani
Journal:  Am J Clin Pathol       Date:  2016-11-14       Impact factor: 2.493

2.  Digital Image Analysis of HER2 Immunostained Gastric and Gastroesophageal Junction Adenocarcinomas.

Authors:  Sofie L Nielsen; Søren Nielsen; Mogens Vyberg
Journal:  Appl Immunohistochem Mol Morphol       Date:  2017 May/Jun

Review 3.  The clinicopathological parameters and prognostic significance of HER2 expression in gastric cancer patients: a meta-analysis of literature.

Authors:  Yu-Ying Lei; Jin-Yu Huang; Qiong-Rui Zhao; Nan Jiang; Hui-Mian Xu; Zhen-Ning Wang; Hai-Qing Li; Shi-Bo Zhang; Zhe Sun
Journal:  World J Surg Oncol       Date:  2017-03-21       Impact factor: 2.754

4.  Clinicopathological features and Borrmann classification associated with HER2-positive in primary gastric cancer.

Authors:  Xiaomin Dai; Xijiong Zhang; Jin Yu
Journal:  Clin Exp Gastroenterol       Date:  2019-06-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.